	Please state all personal interests that you	Please list here any honoraria for advisory	Please state here the connections which exist
Advancing Care in Primary Immunodeficiency Steering Grupo Member	may have in any company which might be perceived to have a conflict of interest with UK Primary Immunodeficiency Network; this includes shares, shares options, etc.	groups or consultative duties paid to you by any company or group which might be perceived to have a conflict of interest with UK Primary Immunodeficiency Network. Please also include any grants made to allow attendance at educational meetings whether this was for registration, accommodation or	between the department in which you work and pharmaceutical companies. This includes investigator led studies, studies led by the pharmaceutical company and other grants and awards. Please also state connections which exist between the department in which you work and any other company
		travel expenses. The precise details and amounts of honoraria, etc. do not need to be stated but each event should be noted	which might be perceived to lead to a conflict of interest with UK Primary Immunodeficiency Network
Peter Arkwright	None	None	None
Claire Bethune	None	None	I am an investigator and the department has recruited patients into multicentre clinical trials, supported by the following pharmaceutical companies: Novartis, BioCryst, Grifols, Shire, Octapharma
Sarah Denman	None	Attendance at EAACI 2016 supported by Shire Attendance at BSACI 2016 supported by Novartis Travel/Accommodation for Excellence in Urticaria 201 meeting supported by Novartis, honorarium paid to pharmacy department education and training account Accommodation for UK Immunology Forum 2017 supported by Shire, honorarium paid to pharmacy department education and training account Attendance at GAZLEN Perceptionship on Urticaria 2017 supported by Novartis Attendance at EAACI 2017 supported by Shire Registration fees for ESID 2017 supported by Grifols Attendance at UKPIN 2017 supported by Octapharma and LFB	Study Co-ordinator on IOS Study (Shire) Research grant received for HAE audit work (Shire)
Lisa Devlin	None	EAACI – 15 th June 2016, sponsorship from CSL Behring (registration/accommodation/travel) ESID 21 st -22 nd September 2016, sponsorship from Shire (registration/accommodation/travel) Novartis urticaria study day 7 th March 2017, speaker fee from Novartis plus travel expenses ESID conference 11 th -13 th September 2017, sponsorship from Grifols (registration/accommodation/travel)	Departmental involvement in the AWARE study (Novartis)
Jill Edmonds	None	UKPIN 2015 – CSL Behring and Octapharma EACCI 2016 – CSL Behring ESID 2016 – CSL Behring Advisory Board for Octapharma	None

Bill Egner	None	None	None
Suzy Elcombe	None	None	None
Tomaz Garcez	None	Attendance at EAACI 2015 supported by CSL Behring Attendance at UKPIN 2015 supported by UKPIN Attendance at EAACI 2016 supported by Shire Honoraria from Shire for advisory board and chairing UK Immunology Forum (both March 2017) Attendance at UK Immunology Forum 2017 supported by Shire Honoraria from CSL Behring for advisory board (May 2017) Attendance at 10 th C1 Inhibitor Deficiency Workshop 217 supported by CSL Behring Attendance at EAACI supported by Shire Attendance at EAACI supported by Shire Attendance at ESID 2017 as Committee/Speaker Attendance at UKPIN as Committee	Investigator on iOS study (Shire) Investigator on OPuS-2 study (BioCryst) Investigator on Prion study (NHS funding) Investigator for UK anaphylaxis death register Department hots the research co-ordinator for the UK PID Registry (UKPIN) Investigator on Zenith study (BioCryst)
Kimberly Gilmour	None	Faculty member ESID CIS summer school – travel and accommodation paid BASIIC speaker – travel and accommodation paid	Servier – UCART cell study Orchard – ADA gene therapy study Genethon – WAS and CGD gene therapy study Bluebird Bio – ALD and beta that gt trials Autolus – CAR gt study Cobalt – CAR gt study
Rashmi Jain	None	I have received grants to allow attendance at educational meetings, for instance UKPIN and Immunology Forum. I was on the advisory board for Shire/Baxalta for Immunoglobulins.	I participated in Opus 2 and Apex clinical trial by BioCryst and in GAN06 trial by Octapharma. I am due to start participation in the iOS study by Shire.
Ravishankar Sargur	None	ESID - Shire EAACI – CSL Behring	None
Sinisa Savic	None	Shire: Honoraria for educational meetings and advisory board, travel expenses CSL Behring: Research grants, honoraria, travel expenses Octapharma: Research grant, honoraria for educational meetings, travel expenses Grifols: Honoraria for educational meeting SOBI: Research grant, honoraria for advisory board meeting and educational sessions, travel expenses Biotest: Honoraria for educational meeting, advisory board	None
Gavin Spickett	None	None	None
Christine Symons	None	Honoraria, travel grants and educational grants received from Shire, CSL Behring, Novartis, Grifols, Octapharma	The Department has undertaken clinical trials on behalf of: Shire, CSL Behring, Novartis, Grifols, Octapharma

Austen Worth	None	I have participated in an advisory group for	Novartis/GSK: vaccines (A phase IIIb, open
		Biotest UK regarding the use of CMV specific	label, controlled, multi-centre study to
		immunoglobulin for the treatment and	evaluate the safety, tolerability and
		prophylaxis of CMV disease post stem cell and	immunogenicity of two doses of Novartis
		solid organ transplant	Meningococcal Group B vaccine when
			administered to immunocompromises
			patients from 2 to 17 years of age who are at
			increased risk of meningococcal disease
			because of complement deficiency or asplenia
			compared to matched healthy subjects
			Genethon: LV gene therapy for Wiskott
			Aldrich Syndrome clinical trial, LV gene
			therapy for CGD clinical trial
			Blue Bio: LV gene therapy for ALD trial
			Novoimmune: Anti IFN gamma for HLH trial
			Orchard Therapeutics: Various gene therapy
			pre-clinical trials